Tobramycin 80mg/2ml Inj, 2ml

• Nephrotoxic drugs (e.g., amphotericin B, cisplatin, cyclosporine, vancomycin, loop diuretics, NSAIDs, contrast media): Increased risk of nephrotoxicity.
• Ototoxic drugs (e.g., loop diuretics, vancomycin, cisplatin): Increased risk of ototoxicity.
• Neuromuscular blocking agents (e.g., succinylcholine, rocuronium, vecuronium): Potentiation of neuromuscular blockade, leading to respiratory depression or paralysis.
• Botulinum toxin: Increased risk of neuromuscular blockade.

• Cephalosporins (especially cephalothin): May increase risk of nephrotoxicity.
• Penicillins (e.g., piperacillin, ticarcillin): In vitro inactivation of tobramycin when mixed in the same IV solution; administer separately. In vivo, synergistic effect is often observed.
• Oral anticoagulants (e.g., warfarin): May enhance anticoagulant effect (rare, possibly due to vitamin K-producing gut flora reduction).

• Magnesium salts: May enhance neuromuscular blockade.

• Hearing loss (difficulty hearing, ringing in ears/tinnitus)
• Balance problems (dizziness, vertigo, unsteadiness, ataxia)
• Kidney problems (decreased urine output, swelling in legs/feet, unusual tiredness)
• Muscle weakness or difficulty breathing (signs of neuromuscular blockade)
• Numbness or tingling (peripheral neuropathy, rare)

Category D. Tobramycin can cause fetal harm when administered to a pregnant woman. Aminoglycosides can cross the placenta and have been associated with reports of total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. While not specifically reported for tobramycin, the risk is considered similar for all aminoglycosides.

Excreted into breast milk in small amounts. Oral absorption by the infant is poor, so systemic effects on the infant are unlikely. However, theoretical risks include disruption of infant gut flora, diarrhea, or candidiasis. Monitor breastfed infant for adverse effects.

Dosing must be carefully calculated based on weight, age, and renal function. Neonates and young infants have immature renal function, requiring longer dosing intervals. Close monitoring of serum levels and renal function is crucial due to increased susceptibility to toxicity.

Elderly patients are at increased risk for nephrotoxicity and ototoxicity due to age-related decline in renal function and pre-existing hearing impairment. Dosing should be based on estimated creatinine clearance, and close monitoring of renal function and serum drug levels is essential.

• Therapeutic drug monitoring (TDM) with peak and trough levels is essential for optimizing efficacy and minimizing toxicity, especially with traditional dosing.
• Extended-interval (once-daily) dosing is often preferred due to reduced nephrotoxicity and comparable efficacy, but requires specific patient selection and monitoring protocols.
• Ensure adequate hydration to minimize the risk of nephrotoxicity.
• Avoid concomitant use with other nephrotoxic or ototoxic drugs whenever possible.
• Patients should be counseled on the importance of reporting any changes in hearing, balance, or urination immediately.
• Tobramycin is often used in combination with beta-lactam antibiotics for synergistic effect against severe Gram-negative infections, but they should not be mixed in the same IV bag due to in vitro inactivation.

• Other aminoglycosides (e.g., gentamicin, amikacin)
• Beta-lactam antibiotics (e.g., piperacillin/tazobactam, ceftazidime, meropenem) for Gram-negative infections
• Fluoroquinolones (e.g., ciprofloxacin, levofloxacin) for susceptible Gram-negative infections
• Colistin (for multi-drug resistant Gram-negative infections)